Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 11/19/25 → 11/19/27 |
Funding
- Bristol Myers Squibb Company: $2.00
25-LUN-145-BMS CA240-0029 A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTA
- Villano, PhD, John (PI)